Provided by Tiger Trade Technology Pte. Ltd.

COMPASS Pathways plc

14.22
-0.9500-6.26%
Post-market: 14.400.1800+1.27%19:35 EDT
Volume:3.32M
Turnover:47.39M
Market Cap:1.96B
PE:-3.94
High:15.01
Open:14.91
Low:14.00
Close:15.17
52wk High:15.87
52wk Low:4.82
Shares:138.00M
Float Shares:107.00M
Volume Ratio:1.06
T/O Rate:3.10%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.6118
EPS(LYR):-3.0800
ROE:-319.07%
ROA:-29.08%
PB:23.21
PE(LYR):-4.62

Loading ...

Analysts Offer Insights on Healthcare Companies: COMPASS Pathways (CMPS) and Tvardi Therapeutics (TVRD)

TIPRANKS
·
Jul 08

Compass Pathways data strengthens launch prospects, says Oppenheimer

TIPRANKS
·
Jul 07

Compass Pathways study data supports benefit of second dose, says Stifel

TIPRANKS
·
Jul 07

Compass Pathways Shares Down 5.4% After Co Reports Late-stage Trial Data for Depression Treatment

THOMSON REUTERS
·
Jul 07

Compass Pathways Publishes Investor Deck on Comp360 Psilocybin Therapy for Treatment-resistant Depression Approval Path

Reuters
·
Jul 07

U.S. Stocks on the Move-tesla, Nvidia, Rivian

Reuters
·
Jul 07

Compass Pathways Shares Gain on Positive Late-stage Trial Data for Depression Treatment

Dow Jones
·
Jul 07

Compass Pathways Shares up 8.6% Premarket After Positive Late-stage Trial Data for Depression Treatment

THOMSON REUTERS
·
Jul 07

Compass Pathways Says Phase 3 Comp006 Study Shows Comp360 Psilocybin Maintains Benefit Through Week 26 in TRD

Reuters
·
Jul 07

Compass Pathways - Comp360 Continues to Show Well-tolerated and Safe Profile with no New Safety Findings

THOMSON REUTERS
·
Jul 07

Compass Pathways Announces Six-month Data from Second Phase 3 Trial Confirming Rapid and Durable Profile

THOMSON REUTERS
·
Jul 07

Compass Pathways - Rolling Nda Submission Underway; Final Submission Expected in Q4

THOMSON REUTERS
·
Jul 07

Compass Pathways - Comp006 Phase 3 Trial Shows Durable Benefit Through 6 Months in Chronic Trd

THOMSON REUTERS
·
Jul 07

Compass Pathways - Commercial Launch of Comp360 Expected in First Half of 2027

THOMSON REUTERS
·
Jul 07

Compass Pathways Grants Inducement Equity Awards to New Hires, Sets Option Exercise Price at $13.29

Reuters
·
Jul 02

Compass Pathways Announces New Employee Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

THOMSON REUTERS
·
Jul 02

Compass Pathways is Maintained at Buy by Canaccord Genuity

Dow Jones
·
Jun 26

European Equities Traded in the US as American Depositary Receipts Decline Friday

MT Newswires Live
·
Jun 26

Compass Pathways price target raised to $20 from $18 at Canaccord

TIPRANKS
·
Jun 26

COMPASS Pathways (CMPS) Receives a Buy from H.C. Wainwright

TIPRANKS
·
Jun 25